Trial · NCT07553767
Registered outcomes50
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 50
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Concentration of Hepatitis B Surface Antigen (Hepatitis B Surface Antigen, HBsAg) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBsAg concentration assessed by Chemiluminescent Microparticle Immunoassay (CMIA). Unit: IU/mL |
| Primary | Proportion of patients with HBsAg loss | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Proportion of patients with HBsAg loss (HBsAg \< 0.05 IU/mL) determined by CMIA. Unit: % of patients |
| Primary | Proportion of patients with HBsAg seroconversion | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Proportion of patients with HBsAg loss (HBsAg \< 0.05 IU/mL) and anti-HBs seropositivity (anti-HBs ≥ 10 mIU/mL) determined by CMIA. Unit: % of patients |
| Secondary | Concentration of HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBV DNA viral load quantified by a TaqMan-based real-time quantitative polymerase chain reaction (qPCR) assay. Unit: IU/mL |
| Secondary | Concentration of Hepatitis B e Antigen (HBeAg) | Baseline, Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240 | Serum HBeAg concentration assessed by CMIA. Unit: S/CO |
| Secondary | Composition and diversity of intestinal microbiota | Baseline, Week 24, Week 48 | Intestinal microbiota analyzed by 16S rRNA gene high-throughput sequencing. Unit: Relative abundance (%) and alpha diversity index |
| Secondary | Recurrence-Free Survival (RFS) | Years 1, 2, 3, 5 | Time to first hepatocellular carcinoma (HCC) recurrence or death from any cause, which is confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). Unit: Months |
| Secondary | Overall survival (OS) | Years 1, 2, 3, 5 | Time from enrollment to death from any cause, regardless of the cause of death. Unit: Months |
| Secondary | Concentration of Interleukin-2 (IL-2) | Baseline, Week 24, Week 48 | Serum levels of IL-2 will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Interleukin-4 (IL-4) | Baseline, Week 24, Week 48 | Serum levels of IL-4 will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Interleukin-6 (IL-6) | Baseline, Week 24, Week 48 | Serum levels of IL-6 will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Interleukin-10 (IL-10) | Baseline, Week 24, Week 48 | Serum levels of IL-10 will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Tumor Necrosis Factor-α (TNF-α) | Baseline, Week 24, Week 48 | Serum levels of TNF-α will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Secondary | Concentration of Interferon-γ (IFN-γ) | Baseline, Week 24, Week 48 | Serum levels of IFN-γ will be measured using cytometric bead array (CBA). Unit: pg/mL |
| Other | The Levels of Thyroid Stimulating Hormone (TSH) | Baseline, Weeks 12, 24, 36, 48 | TSH measured by chemiluminescent immunoassay (CLIA). Unit: mIU/L |
| Other | The Levels of Free Triiodothyronine (FT3) | Baseline, Weeks 12, 24, 36, 48 | FT3 measured by chemiluminescent immunoassay (CLIA). Unit: pmol/L |
| Other | The Levels of Free Thyroxine (FT4) | Baseline, Weeks 12, 24, 36, 48 | FT4 measured by chemiluminescent immunoassay (CLIA). Unit: pmol/L |
| Other | The Levels of Thyroglobulin Antibody (TgAb) | Baseline, Weeks 12, 24, 36, 48 | TgAb measured by chemiluminescent immunoassay (CLIA). Unit: IU/mL |
| Other | The Levels of Thyroid Peroxidase Antibody (TPOAb) | Baseline, Weeks 12, 24, 36, 48 | TPOAb measured by chemiluminescent immunoassay (CLIA). Unit: IU/mL |
| Other | Concentration of Alpha-fetoprotein (AFP) | Baseline, Weeks 12, 24, 36, 48, 96, 144, 192 | AFP measured by CLIA. Unit: ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07553767/registered